Tenaya Therapeutics (TNYA) Enterprise Value (2020 - 2026)

Tenaya Therapeutics' Enterprise Value history runs 7 years deep, the most recent figure standing at -$80.9 million for Q1 2026.

• On a quarterly basis, Enterprise Value rose 8.23% year-over-year to -$80.9 million in Q1 2026; TTM through Mar 2026 was -$80.9 million, a 8.23% increase from a year earlier, with the FY2025 full-year figure at -$100.5 million, down 63.63% from the prior year.
• Enterprise Value grew to -$80.9 million in Q1 2026 per TNYA's latest filing, from -$100.5 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$56.3 million in Q3 2025 and bottomed at -$210.5 million in Q1 2022.
• The 5-year median for Enterprise Value is -$104.6 million (2023), against an average of -$117.8 million.
• Biggest YoY gain for Enterprise Value was 46.71% in 2022; the steepest drop was 63.86% in 2022.
• Year by year, Enterprise Value stood at -$186.5 million in 2022, then jumped by 43.9% to -$104.6 million in 2023, then soared by 41.28% to -$61.4 million in 2024, then sank by 63.63% to -$100.5 million in 2025, then rose by 19.54% to -$80.9 million in 2026.
• Per Business Quant, the three latest TNYA Enterprise Value figures stand at -$80.9 million (Q1 2026), -$100.5 million (Q4 2025), and -$56.3 million (Q3 2025).